Dacarbazine and the Agonistic TRAIL Receptor-2 Antibody Lexatumumab Induce Synergistic Anticancer Effects in MelanomaBirgit Engesæter, Gunhild M. Mælandsmo|PLoS ONE|2012Cited by 15
hvTRA, a novel TRAIL receptor agonist, induces apoptosis and sustained growth retardation in melanomaKarianne G. Fleten, Birgit Engesæter|Cell Death Discovery|2016Cited by 13